Fulcrum Therapeutics(FULC) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

FULC Fulcrum Therapeutics

Watchlist

3.140
-0.080-2.48%

Close Mar 7 16:00 ET

3.140
0.0000.00%

Post 17:56 ET

169.50MMarket Cap-19.63P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
BenzingaMar 5 13:21 ET
Fulcrum Therapeutics Has Received Written Notice From Bristol Myers Squibb-Acquired MyoKardia To End Their Collaboration And License Agreement, Originally Signed On July 20, 2020, The Termination Will Officially Take Effect On June 26, 2025-8K
BenzingaMar 5 06:46 ET
Fulcrum Therapeutics Faces Termination of Key Agreement
TipRanksMar 4 17:27 ET
Express News | Fulcrum Therapeutics Inc - Termination Effective June 26, 2025
ReutersMar 4 17:03 ET
Express News | Fulcrum Therapeutics Inc - Myokardia Terminates Collaboration and License Agreement With Co
ReutersMar 4 17:03 ET
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
GlobeNewswireMar 4 16:05 ET

Comments

Jaguar8

Sep 12, 2024 07:11

NEWS

$Fulcrum Therapeutics (FULC.US)$
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...

Trytosaveabit

Jul 31, 2024 12:53

Up is the way!

$Fulcrum Therapeutics (FULC.US)$ Low volume indeed! But low or high volume, all that matters is that it’s moving up nicely

Trytosaveabit

Jul 31, 2024 06:11

Talk about a under estimated or a killer unexpected operating income! Hehehe!

$Fulcrum Therapeutics (FULC.US)$ Fulcrum Therapeutics Q2 Operating Income USD 52.492 Million Vs. IBES Estimate USD 361.4 Thousand! Hope the rest of the earnings looks like this? hehehe

Trytosaveabit

May 23, 2024 08:23

Note the timeline

$Fulcrum Therapeutics (FULC.US)$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.

jimmy the trader

May 14, 2024 14:06

Oh come on what are you waiting for we all know we goin up

$Fulcrum Therapeutics (FULC.US)$ Oh come on what are you waiting for we all know we goin up

FULC Fulcrum Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks